RISK

Trading carries substantial risk of loss. Prop evaluation fees are typically non-refundable and the majority of traders do not pass first attempts. This comparison is for informational purposes only and does not constitute financial advice. Read full risk warning

HEAD-TO-HEAD COMPARISON · 2026

DNA Funded vs ATFunded

Side-by-side comparison of trust scores, profit splits, payout speed, and real trader reviews. Independent data — no sponsored rankings.

DNAF

DNA Funded

ATFD

ATFunded

DNA FUNDED

METRIC

ATFUNDED

0/100TIE

TRUST SCORE

TIE0/100

0/5TIE

RATING

TIE0/5

—

PROFIT SPLIT

80%

—

MAX FUNDING

$200,000

—

MIN COST

$49

—

PAYOUT DAYS

14d

—

PASS RATE

—

0TIE

REVIEW COUNT

TIE0

DNA FUNDED DETAILS

STEPS: -phase

ATFUNDED DETAILS

STEPS: 2-phase
DRAWDOWN: Trailing EOD
MARKETS: Forex, Indices, Commodities, Crypto

DNA Funded PROS

+No performance data is available to identify any above-average metrics for this firm
+No fee, payout, or structure data provided to evaluate competitiveness
+No platform or market data available to assess trading flexibility
+Country of operation (Australia) is noted, but no regulatory or structural data exists

DNA Funded CONS

−No data is provided for this firm, making any meaningful comparison impossible
−Traders cannot assess profit split, funding, or costs against the 84.7% and $186.7 averages
−Complete absence of data is a significant transparency concern for traders making financial decisions

ATFunded PROS

+Min challenge cost of $49 is well below the industry average of $186.7, making entry very affordable.
+EA/automated trading is permitted, supporting algorithmic and systematic trading strategies.
+Overall drawdown of 10% is above the industry average of 7.9%, offering more buffer before a breach occurs.
+Multi-market access including Forex, Indices, Commodities, and Crypto provides good diversification options.

ATFunded CONS

−Profit split of 80% is below the industry average of 84.7%, meaning traders retain less of their profits.
−Max funding of $200,000 is significantly below the industry average of $839,272.7, limiting earning potential.
−Days to first payout at 14 is more than double the industry average of 6.5 days, significantly slowing cash flow.

PROPDNA VERDICT

DNA Funded

Higher trust score (0/100). Slower payouts at —d.

START WITH DNAF